



## ASX ANNOUNCEMENT

### 28 August 2015

---

### Lapse of Share Options

**Melbourne, Australia, 28 August 2015:** Genetic Technologies Limited advises that 10,150,000 unlisted share options granted pursuant to the Company's employee option plan have lapsed. The details of these lapsed options are:

Unlisted employee option reference	Exercise price	Options lapsed
GTGAO (expiring 29 August 2017)	\$0.14	2,400,000
GTGAA (expiring 31 May 2019)	\$0.04	5,500,000
GTGAQ (expiring 1 December 2017)	\$0.10	250,000
GTGAS (expiring 25 January 2018)	\$0.10	500,000
GTGAK (expiring 20 February 2017)	\$0.12	500,000
GTGAW (expiring 31 March 2016)	\$0.19	500,000
GTGAY (expiring 11 July 2018)	\$0.105	500,000
<b>Total</b>		<b>10,150,000</b>

Accordingly, as at the date of this announcement, as summarises below, there are a total of 24,241,667 outstanding options over shares in the Company.

<b>Unlisted employee options</b>		
GTGAM (expiring 31 July 2016)	\$0.20	1,000,000
GTGAO (expiring 29 August 2017)	\$0.14	250,000
GTGAW (expiring 31 March 2016)	\$0.19	1,250,000
GTGAY (expiring 11 July 2018)	\$0.105	250,000
GTGAA (expiring 31 May 2019)	\$0.04	1,125,000
<b>Unlisted options attached to convertible notes</b>		
GTGAC (expiring 2 December 2018)	\$0.015	20,366,667
<b>Total</b>		<b>24,241,667</b>



FOR FURTHER INFORMATION PLEASE CONTACT

**Mr. Eutillio Buccilli**  
Executive Director &  
Chief Executive Officer  
Genetic Technologies Limited  
+ 61 3 8412 7050

**Candice Knoll (USA)**  
Blueprint Life Science Group  
+1 (415) 375 3340, Ext. 105

#### **About Genetic Technologies Limited**

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The Company's lead product, BREVAGen<sup>plus</sup><sup>®</sup>, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGen<sup>plus</sup><sup>®</sup> improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGen<sup>plus</sup><sup>®</sup> expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGen<sup>plus</sup><sup>®</sup>, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGen<sup>plus</sup><sup>®</sup> to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).

For more information, please visit [www.brevagenplus.com](http://www.brevagenplus.com) and [www.phenogensciences.com](http://www.phenogensciences.com).

#### **Safe Harbor Statement**

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the [Private Securities Litigation Reform Act](#). The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.